Accordingly, several IGF-1R inhibitors have reached different stages of anti-cancer clinical development; yet none have been approved for clinical application due to complications like hyperglycemia and hyperinsulinemia [118]. The gene discussed is IGF1R; the disease is Hyperglycemia.